CYT009-GhrQb: Phase I/II started

CYTN began a double-blind, placebo-controlled, dose-ranging Phase I/II trial in 112 obese subjects with a body mass index (BMI) between 30 and 35. The subjects will receive 3 doses of the vaccine or p...